Sugi Predict

Sugi Predict / Targets / CCNE1

CCNE1

G1/S-specific cyclin-E1 · P24864 · CCNE1 on Sugi Atlas →

186,152 patent compounds predicted against CCNE1, 110,754 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL103715 SCHEMBL103715 0.66 19/20
SCHEMBL12466 SCHEMBL12466 0.58 16/20
SCHEMBL12292 SCHEMBL12292 0.59 15/20
SCHEMBL268925 SCHEMBL268925 0.50 14/20
SCHEMBL269583 SCHEMBL269583 0.50 14/20
SCHEMBL179490 SCHEMBL179490 0.52 13/20
SCHEMBL160631 SCHEMBL160631 0.40 11/20
Clonazepam Clonazepam (SCHEMBL38899) 0.59 10/20
SCHEMBL285629 SCHEMBL285629 0.65 9/20
SCHEMBL239486 SCHEMBL239486 0.34 9/20
SCHEMBL240231 SCHEMBL240231 0.34 9/20
Bms-387032 Bms-387032 (SCHEMBL187401) 1.00 8/20
SCHEMBL183185 SCHEMBL183185 0.55 8/20
SCHEMBL186141 SCHEMBL186141 0.50 8/20
SCHEMBL84453 SCHEMBL84453 0.48 8/20
Seliciclib Seliciclib (SCHEMBL94728) 1.00 7/20
(Rs)-Roscovitine (Rs)-Roscovitine (SCHEMBL172593) 1.00 7/20
SCHEMBL183273 SCHEMBL183273 0.58 7/20
SCHEMBL91448 SCHEMBL91448 0.47 7/20
SCHEMBL37886 SCHEMBL37886 0.45 7/20

Clinical trials — most relevant to CCNE1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy PHASE2COMPLETED
Study of AVZO-021 in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients PHASE2COMPLETED
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors PHASE1/PHASE2COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors PHASE2WITHDRAWN
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency PHASE2COMPLETED
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) PHASE2COMPLETED
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors PHASE1RECRUITING
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia PHASE1WITHDRAWN
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors PHASE1WITHDRAWN
Study of SGR-3515 In Participants With Advanced Solid Tumors. PHASE1RECRUITING
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma PHASE1WITHDRAWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCNE1 binder may also engage these)

ProteinNameSimilarity
Q61457 — 0.998 Q61457 →
P49707 — 0.997 P49707 →
P39949 — 0.997 P39949 →
P50756 — 0.995 P50756 →
Q91780 — 0.995 Q91780 →
O15995 — 0.993 O15995 →
O42575 — 0.993 O42575 →
P47794 — 0.993 P47794 →
CCNE2 G1/S-specific cyclin-E2 0.992 landscape →
Q9Z238 — 0.991 Q9Z238 →
P25322 — 0.988 P25322 →
P39948 — 0.987 P39948 →
CCND1 G1/S-specific cyclin-D1 0.987 landscape →
Q2KI22 — 0.986 Q2KI22 →
Q5R6J5 — 0.986 Q5R6J5 →
Q5E9K7 — 0.985 Q5E9K7 →
Q64HP0 — 0.984 Q64HP0 →
Q16589 — 0.982 Q16589 →
P55169 — 0.982 P55169 →
Q90459 — 0.982 Q90459 →
P49706 — 0.980 P49706 →
Q0P5D3 — 0.980 Q0P5D3 →
Q8WNW2 — 0.979 Q8WNW2 →
Q9D995 — 0.979 Q9D995 →
P30280 — 0.979 P30280 →
Q7T0L6 — 0.979 Q7T0L6 →
Q8N815 — 0.979 Q8N815 →
P50755 — 0.977 P50755 →
Q04827 — 0.977 Q04827 →
P53782 — 0.976 P53782 →